Navigation Links
TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer

PHILADELPHIA, Dec. 10, 2012 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced that Dalvir Gill, PhD, has been appointed Chief Executive Officer, effective January 1, 2013. Dr. Gill will lead the independent non-profit entity, which was formed by ten healthcare and pharmaceutical companies in September to improve the quality of clinical studies and bring new medicines to patients faster by facilitating the collaboration required to solve common challenges encountered during the clinical trial process. Dr. Gill will succeed Garry Neil, MD, who has served as interim CEO of TransCelerate since the organization was formed in September. Dr. Neil will remain as Chairman of the Board of Directors for TransCelerate.

TransCelerate member organizations are currently working together on improving clinical study execution. Under this program, TransCelerate seeks to provide the following solutions for clinical trials: development of a shared user interface for investigator site portals, mutual recognition of study site qualification and training, development of risk-based site monitoring approach and standards, development of clinical data standards, and establishment of a comparator drug supply model.

"I am honored to lead this organization and work with the global research and development community to assess, refine and create processes to bring innovative new medicine to the public faster," said Dr. Gill.

Dr. Gill has more than 25 years of drug development experience. Prior to his appointment as CEO of TransCelerate, Dr. Gill was the President of Phase II-IV Drug Development at PharmaNet-i3, an organization specializing in drug development services. In this role, Dr. Gill was responsible for a global business spanning nearly 40 countries.

"Dr. Gill is a recognized industry leader with a proven history of success in the field of drug development. His deep experience across the pharmaceutical industry will help TransCelerate to advance key initiatives and provide solutions that will have measurable impact for patients worldwide," said Dr. Neil, Partner and Head of Pharmaceutical Research and Development at Apple Tree Partners.

Dr. Gill earned his BS in Applied Biology from the University of Hertfordshire and his PhD in Pathobiology from the Royal Free Hospital School of Medicine, University of London. He also holds a diploma in the health economics of pharmaceuticals from the executive program of the Stockholm School of Economics. Dr. Gill has presented his research and spoken at numerous conferences and has authored over 30 scientific publications. He also is an elected fellow of the Royal Society of Medicine.

About TransCelerate BioPharma Inc.

TransCelerate BioPharma Inc. is a non-profit organization established to simplify drug development challenges and accelerate the delivery of new medicines for patients by creating solutions to make clinical trial execution more efficient. The organization evolved from relationships fostered via the Hever Group, a forum for executive R&D leadership to discuss relevant issues facing the industry and solutions for addressing common challenges. Founding members include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech a member of the Roche Group, and Sanofi, and all have representation on the Board of Directors. Membership in TransCelerate is open to all pharmaceutical and biotechnology companies who can contribute to and benefit from these shared solutions. TransCelerate's headquarters are located in Philadelphia, PA.


Media Contacts (Porter Novelli):

Virginia Amann


Shannon Caudill

740.281.3715 or 614.378.9042

SOURCE TransCelerate BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
2. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
3. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
5. John A. Orwin Joins Array BioPharma Board Of Directors
6. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
7. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
8. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
9. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
10. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
11. PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
Post Your Comments:
(Date:11/27/2015)... India , November 27, 2015 /PRNewswire/ ... --> Growing popularity of companion diagnostics ... in cancer biomarkers market with pharmaceutical companies ... in-demand companion diagnostic tests. ... --> Complete report on global cancer ...
(Date:11/25/2015)... 2 nouvelles études permettent d , identifier ... souches bactériennes retrouvées dans la plaque dentaire des ... Ces recherches  ouvrent une nouvelle voie ... l,un des problèmes de santé les plus fréquemm ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
(Date:11/24/2015)... HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... as the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, ... golf through his or her work with turfgrass. , Clarke, of Iselin, ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th ... Paris from 17 th until 19 th ... leader, has invented the first combined scanner in the world ... scanning surface. Until now two different scanners were required: one ... both on the same surface. This innovation is an ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
Breaking Biology News(10 mins):